Vitamin K1 Concentration in Breast‐Fed Neonates After Oral or Intramuscular Administration of a Single Dose of a New Mixed‐Micellar Preparation of Phylloquinone

Abstract

SummaryThe plasma disposition of a new mixedmicellar preparation (KONAKION MM, Roche) of phylloquinone (vitamin K1) has been studied in 25 healthy, fully breast‐fed, newborn babies, randomized to receive a single dose of either 1.5 mg i.m. (11 babies) or 3 mg p.o. (14 babies). Venous blood samples were collected at 25 h, 4 days, and 24 days. After p.o. administration, the median plasma phylloquinone concentration increased to 89 ng/ml after 24 h, then decreased to 51 ng/ml after 4 days; the respective concentrations after i.m. injection were 146 ng/ml and 34 ng/ml. The higher plasma phylloquinone level in the i.m. group after 24 h was not statistically significant compared with that of the p.o. group, but the reversed higher concentration in the p.o. group after 4 days was significant (p < 0.01). After 24 days the median plasma phylloquinone had decreased to 0.44 ng/ml (range 0.19–1.44) and 1.05 ng/ml (range 0.37–1.87) in the p.o. and i.m. groups, respectively. There was a significant difference between these plasma concentrations (p < 0.01). They were within or above the reference adult fasting range (0.17–0.68 ng/ml). The narrow range of plasma concentrations at 24 h and 4 days suggests a greater consistency of absorption from this micellar preparation than from other emulsion‐based preparations. Further studies are required to assess the long‐term protection of a single oral dose against late hemorrhagic disease of the newborn. Until such time, breast‐fed babies given this preparation orally should receive (an) additional dose(s).